AI-designed immune sensor-enhanced CAR-T cells for potent solid tumor immunotherapy

Immune-based therapies have revolutionized cancer treatment; however, their efficacy in solid tumors remains limited. This is primarily due to the immunosuppressive tumor microenvironment (TME) and insufficient induction of systemic anti-tumor immunity. To overcome these barriers, Edity Therapeutics has developed an AI-guided platform that integrates engineered innate immune sensors into CAR-T cells. These sensors are designed to initiate a localized antiviral-like immune response upon antigen engagement. Immune sensors derived from the STING and MAVS pathways were computationally optimized to generate constitutively active, yet controllable, derivatives that drive Type I interferon and pro-inflammatory cytokine production. These sensor modules were fused to a navigator domain, ensuring their activation is exclusively upon CAR signaling, thereby confining immune stimulation to the tumor site. Hundreds of sensor variants were designed and screened in vitro for functional potency. Lead candidates exhibiting strong immuno-stimulatory activity were incorporated into CAR-T constructs and evaluated in SCID-Beige xenograft models. In these models, sensor-enhanced CAR-T cells demonstrated significantly superior tumor control compared to conventional CAR-T counterparts. By locally provoking inflammation, this approach will convert the immune-cold TME into an inflamed tumor milieu, potentially enabling robust anti-tumor responses without inducing peripheral adverse effects. The platform is currently being advanced toward clinical development, with two solid tumor indications selected based on antigen expression, tumor accessibility, and translational readiness. These next-generation CAR-T products represent a new class of cell therapies that couple precise tumor targeting with controlled autonomous immune activation, offering a transformative approach for the treatment of solid malignancies while improving the therapeutic index.